Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to penetrate the corneal membrane effectively. Rapid tear turnover further diminishes drug concentration at the absorption site. When drugs also have a short half-life, maintaining therapeutic levels becomes difficult, often requiring frequent dosing. This increases the risk of both local side effects, like irritation, and systemic exposure. Enhancing drug contact time with the eye is a common strategy to address this challenge. Viscous formulations such as ointments and suspensions can help, but they lack precise control over drug release.

A more effective solution involves controlled-release systems that provide continuous drug delivery. These systems minimize dosing frequency and reduce side effects by maintaining consistent drug levels. Ocular inserts, such as the ocusert system, exemplify this approach. Designed for glaucoma treatment, ocuserts deliver pilocarpine at controlled rates of 20 or 40 micrograms per hour. Inserted into the lower fornix conjunctiva, they maintain therapeutic levels for up to seven days, compared to conventional eye drops that require multiple daily applications. The ocusert consists of a thin, flexible core reservoir containing the drug, enclosed between two rate-controlling membranes made of ethylene-vinyl acetate copolymer. This configuration enables zero-order drug release, improving treatment outcomes while reducing patient burden. Advances in these systems continue to improve precision, compliance, and overall effectiveness in ophthalmic therapy.